These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25911083)

  • 1. Use of lipid-lowering medications in myasthenia gravis: a case report and literature review.
    Ragbourne SC; Crook MA
    J Clin Lipidol; 2015; 9(2):256-9. PubMed ID: 25911083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins can induce myasthenia gravis.
    Gale J; Danesh-Meyer HV
    J Clin Neurosci; 2014 Feb; 21(2):195-7. PubMed ID: 24433954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins and Myasthenia Gravis.
    Khalid R; Ibad A; Thompson PD
    Muscle Nerve; 2016 Sep; 54(3):509. PubMed ID: 27105400
    [No Abstract]   [Full Text] [Related]  

  • 4. More evidence for the association between statins and myasthenia gravis.
    de Sousa E; Howard J
    Muscle Nerve; 2008 Sep; 38(3):1085-6. PubMed ID: 18720505
    [No Abstract]   [Full Text] [Related]  

  • 5. Statins may aggravate myasthenia gravis.
    Oh SJ; Dhall R; Young A; Morgan MB; Lu L; Claussen GC
    Muscle Nerve; 2008 Sep; 38(3):1101-7. PubMed ID: 18720508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety update: statins and myasthenia gravis.
    Drug Ther Bull; 2023 Dec; 62(1):4. PubMed ID: 38050092
    [No Abstract]   [Full Text] [Related]  

  • 7. A rare association of myasthenia gravis and mitochondrial myopathy: a clinical, biochemical and morphologic study of one case.
    Plewnia K; Dotti MT; Malandrini A; Manneschi L; Battisti C; De Stefano N; Rufa A; Motolese E; Federico A
    J Submicrosc Cytol Pathol; 1997 Jul; 29(3):335-8. PubMed ID: 9267042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin-associated ocular myopathy mimicking ocular myasthenia: Rare occurrence.
    Mahale R; Mehta A; Kempegowda MB; Shankar AK; John AA; Javali M; Srinivasa R
    Neurol India; 2016; 64(4):785-6. PubMed ID: 27381128
    [No Abstract]   [Full Text] [Related]  

  • 9. Statin-associated myasthenic weakness.
    Pasutharnchat N; Phanthumchinda K
    J Med Assoc Thai; 2011 Feb; 94(2):256-8. PubMed ID: 21534375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chiari type I malformation: a mimicker of myasthenia gravis.
    Muthusamy P; Matte G; Kosmorsky G; Chémali KR
    Neurologist; 2011 Mar; 17(2):86-8. PubMed ID: 21364360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Exacerbation of pseudoparalytic myasthenia gravis following azithromycin (Zithromax)].
    Cadisch R; Streit E; Hartmann K
    Schweiz Med Wochenschr; 1996 Feb; 126(8):308-10. PubMed ID: 8701248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin-induced myasthenia: A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
    Gras-Champel V; Batteux B; Masmoudi K; Liabeuf S
    Muscle Nerve; 2019 Oct; 60(4):382-386. PubMed ID: 31298743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Hou R; Goldberg AC
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):79-97. PubMed ID: 19217513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eye on statins: A comprehensive review.
    Olson EA; Hainsworth DP; Davis G; Hagan JC
    Mo Med; 2013; 110(4):344-8. PubMed ID: 24003655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bibliometric analysis of the scientific production as regards statin use for ophthalmological symptoms of myasthenia gravis.
    Salado-Font SM; López-Muñoz F; Povedano-Montero FJ; Labella Quesada F
    Arch Soc Esp Oftalmol; 2017 Oct; 92(10):464-471. PubMed ID: 28318833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-glucans reduce LDL cholesterol in patients with myasthenia gravis.
    Haggård L; Andersson M; Punga AR
    Eur J Clin Nutr; 2013 Feb; 67(2):226-7. PubMed ID: 23187951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
    Lancellotti P; Pierard LA; Scheen AJ
    Rev Med Liege; 2015 Sep; 70(9):450-5. PubMed ID: 26638446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between lipid-lowering agents and severe hyponatremia: a population-based case-control study.
    Skov J; Falhammar H; Calissendorff J; Lindh JD; Mannheimer B
    Eur J Clin Pharmacol; 2021 May; 77(5):747-755. PubMed ID: 33215235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progressive muscle weakness: More there than meets the eye.
    Albashir S; Olansky L; Sasidhar M
    Cleve Clin J Med; 2011 Jun; 78(6):385-91. PubMed ID: 21632910
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins.
    Stein EA; Ballantyne CM; Windler E; Sirnes PA; Sussekov A; Yigit Z; Seper C; Gimpelewicz CR
    Am J Cardiol; 2008 Feb; 101(4):490-6. PubMed ID: 18312764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.